Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Express Scripts
McKesson
Dow
Colorcon

Last Updated: August 19, 2022

Investigational Drug Information for MLN1117


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug MLN1117?

MLN1117 is an investigational drug.

There have been 8 clinical trials for MLN1117. The most recent clinical trial was a Phase 2 trial, which was initiated on June 30th 2016.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, Non-Small-Cell Lung, and Endometrial Neoplasms. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., European Network of Individualized Treatment in Endometrial Cancer - ENITEC, and European Network of Translational Research in Ovarian Cancer - EUTROC.

There are seven US patents protecting this investigational drug and ninety-six international patents.

Recent Clinical Trials for MLN1117
TitleSponsorPhase
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid TumorsAvera McKennan Hospital & University Health CenterPhase 1
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaMillennium Pharmaceuticals, Inc.Phase 2
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial CancerEuropean Network of Individualized Treatment in Endometrial Cancer - ENITECPhase 2

See all MLN1117 clinical trials

Clinical Trial Summary for MLN1117

Top disease conditions for MLN1117
Top clinical trial sponsors for MLN1117

See all MLN1117 clinical trials

US Patents for MLN1117

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MLN1117 See Plans and Pricing Combination of PI3K-inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) See Plans and Pricing
MLN1117 See Plans and Pricing Crystalline forms Array Biopharma Inc. (Boulder, CO) See Plans and Pricing
MLN1117 See Plans and Pricing Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile Loxo Oncology Inc. (Stamford, CT) See Plans and Pricing
MLN1117 See Plans and Pricing Heterocyclic compounds and uses thereof INTELLIKINE, INC. (La Jolla, CA) See Plans and Pricing
MLN1117 See Plans and Pricing Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof Intellikine LLC (La Jolla, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MLN1117

Drugname Country Document Number Estimated Expiration Related US Patent
MLN1117 European Patent Office EP3077003 2033-12-03 See Plans and Pricing
MLN1117 World Intellectual Property Organization (WIPO) WO2015082378 2033-12-03 See Plans and Pricing
MLN1117 Argentina AR113760 2037-10-10 See Plans and Pricing
MLN1117 Australia AU2018348161 2037-10-10 See Plans and Pricing
MLN1117 Brazil BR112020005463 2037-10-10 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Express Scripts
McKesson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.